901 Gateway Boulevard
South San Francisco
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the Closed Triple), currently in development for the treatment of COPD and asthma.
121 articles with Theravance Biopharma
Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
Additional Analyses of Phase 3 Program Data Highlight Efficacy Advantages for 175 mcg/day of YUPELRI in Key Patient Subgroups, Demonstrate Acceptable Cardiovascular Safety Profile
Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Presentation to Highlight Positive Data Demonstrating Localized Target Engagement and Minimal Systemic Exposure following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colitis
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
Presentations Highlight Data of YUPELRI Compared with Tiotropium in Subpopulation of COPD Patients with Suboptimal Peak Inspiratory Flow Rates, Report Additional Data from Pivotal Phase 3 Program in Patients with Moderate to Very Severe COPD
Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe
Trelegy Ellipta is the triple combination therapy of FF/UMEC/VI in a single ELLIPTA® inhaler.
Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress
Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRITM Compared to Placebo and Tiotropium (Spiriva® HandiHaler®)
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
Industry veteran to lead and execute operations for pivotal Phase 3 SIERRA trial for Iomab-B.
Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced positive four-week results from a Phase 2 clinical trial of TD-9855, an investigational, once-daily norepinephrine and serotonin reuptake inhibitor (NSRI) in development for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH).
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Healthcare Conference on Thursday, May 17, 2018, at 10:40 a.m. PT. The conference will be held May 15 - 17 at the Encore Wynn in Las Vegas.
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
Plenty of exciting news in the research world. Here’s a look at some of the top stories.
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates in Elderly and Obese Patients Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor Antibiotics Against Difficult-to-Treat Staphylococcus aureus Pathogens including Challenging Multidrug Resistant (MDR) MRSA Isolates
Johnson & Johnson is hoping its $100 million deal with Theravance will serve as a replacement for Remicade which lost patent protection.
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta
If this latest submission is approved, the labeled indication for Trelegy Ellipta would include a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy.
J&J inked a global collaboration deal with Theravance Biopharma to develop a drug for IBD.
Theravance Biopharma and Mylan Announce FDA Acceptance of NDA for Revefenacin (TD-4208) in Adults With COPD
The FDA has assigned a PDUFA target action date of November 13, 2018, and indicated that it does not currently plan to convene an advisory committee meeting to discuss the NDA.
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta
If this sNDA is approved, the labeled indication for Trelegy Ellipta would include a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy.
Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD
Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by Glaxo or one of its affiliates pursuant to its agreements with Innoviva.
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults With COPD
The NDA is supported by the companies' Phase III program for revefenacin, which consisted of two replicate pivotal Phase III efficacy studies and a 12-month, open-label, active comparator safety study.
Theravance Biopharma Reports Positive New Data From Multiple Studies Of VIBATIV (Telavancin) At IDWeek 2017